Investigational New Drugs

, Volume 6, Issue 3, pp 207–210

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

Authors

  • Daniele J. Perrault
    • OCTRF, Ottawa Regional Cancer Centre
  • Diane M. Logan
    • OCTRF, Ottawa Regional Cancer Centre
  • David J. Stewart
    • OCTRF, Ottawa Regional Cancer Centre
  • Vivien H. C. Bramwell
    • OCTRF, London Regional Cancer Centre
  • Alexander H. G. Paterson
    • Cross Cancer Institute
  • Elizabeth A. Eisenhauer
    • NCIC Clinical Trials GroupQueen's University
Clinical Studies

DOI: 10.1007/BF00175399

Cite this article as:
Perrault, D.J., Logan, D.M., Stewart, D.J. et al. Invest New Drugs (1988) 6: 207. doi:10.1007/BF00175399

Summary

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis. Toxicity occurred in 18 of the 33 patients and was primarily gastrointestinal. It ranged in severity from mild to severe with 4 patients discontinuing treatment early because of nausea, vomiting, diarrhea or stomatitis. One response, of 8 weeks duration, was noted in 29 evaluable patients. We conclude that flutamide does not have meaningful anti-tumour activity in breast cancer and plan no further trials of the drug in this disease.

Key words

breast cancerhormone therapyflutamide

Copyright information

© Kluwer Academic Publishers 1988